Leidos/$LDOS

1D1W1MYTD1Y5YMAX

About Leidos

Leidos Holdings Inc is a technology, engineering, and science company that provides services and solutions in the defense, intelligence, civil, and health management, both domestically and internationally. The customers of the company includes the U.S. Department of Defense ("DoD"), the U.S. Intelligence Community, the U.S. Department of Homeland Security ("DHS"), the Federal Aviation Administration ("FAA"), the Department of Veterans Affairs ("VA"), and many other U.S. civilian, state and local government agencies, etc. The company is engaged in four reportable segments; National Security & Digital, Health & Civil, Commercial & International and Defense Systems. It provides a wide array of scientific, engineering and technical services and solutions across these reportable segments.
Ticker
$LDOS
Sector
Business services
Primary listing
NYSE
Employees
50,000

Leidos Metrics

BasicAdvanced
$15B
11.52
$10.71
0.57
$1.69
1.39%

What the Analysts think about Leidos

Analyst ratings (Buy, Hold, Sell) for Leidos stock.
Analyst projections of the future price of Leidos stock.

Bulls say / Bears say

On May 5, 2026, Leidos raised its full-year 2026 profit and revenue forecast, citing strong demand for its IT and military intelligence services from the Pentagon and U.S. intelligence agencies (Reuters)
On August 4, 2026, the company lifted the lower end of its 2026 revenue guidance to $18.2–$18.4 billion and raised adjusted EPS forecasts, attributing the upgrade to heightened geopolitical tensions driving defense technology demand (Reuters)
In Q2 2026, Leidos delivered $4.56 billion in revenue (up 7.2% YoY) and non-GAAP diluted EPS of $3.26 (12% beat vs. estimates), prompting management to raise the midpoint of full-year revenue guidance to approximately $18.3 billion (Investing.com)
Leidos’ fourth-quarter 2025 revenue came in at $4.21 billion, missing analysts’ $4.31 billion estimate as the six-week U.S. government shutdown weighed on its federal orders, underscoring its vulnerability to budgetary disruptions (Reuters)
Gross margin compressed to 17.9% in Q2 2026 from 18.4% a year ago, while non-GAAP operating margin declined to 11.3% from 13.4%, reflecting integration costs and margin pressure post-acquisitions (MarketBeat)
Bank of America downgraded Leidos from Buy to Neutral on June 16, 2026 and cut its price target to $125 from $200, citing intensifying pressure on its healthcare segment and moderating growth prospects (MarketScreener)
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2026.

Leidos Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Leidos Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing Leidos

AllEURGBPUSD
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.